COMUNICADO: FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Pri

Publicado 29/11/2016 14:24:22CET

1) Kaufman HL, et al. Avelumab in patients with chemotherapy-refractory metastatic
Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet
Oncology. 2016;17(10);1374-85.
2) Fitzgerald T et al. Dramatic increase in the incidence and mortality from Merkel cell
carcinoma in the United States. The American Journal of Surgery. 2015;81(8):802-6.
3) FDA. Priority Review.
Last accessed October 2016.
4) National Cancer Institute. Merkel cell carcinoma treatment-patient version (PDQ(R)). Last accessed
October 2016.
5) American Cancer Society. What is Merkel cell carcinoma?
[ ]
Last accessed October 2016.
6) Desch L and Kuntsfeld R. Merkel cell carcinoma: chemotherapy and emerging new
therapeutic options. Journal of Skin Cancer. 2013(2013):327150.
7) Heath M, Jaimes N and Lemos B. Clinical characteristics of Merkel cell carcinoma at
diagnosis in 195 patients: the AEIOU features. Journal of the American Academy of
Dermatology. 2008;58:375-81.
8) Poulsen M. Merkel cell carcinoma of skin: diagnosis and management strategies. Drugs
Aging. 2005;22(3):219-29.
9) Swann MH and Yoon J. Merkel cell carcinoma. Seminars in Oncology. 2008;34(1):51-56.
10) NCCN Merkel Cell Carcinoma Guidelines version I. 2017. Last accessed October


CONTACT: Your Contacts: Merck - Media: Gangolf Schrimpf, +49 6151 72 9591;Investor Relations, +49 6151 72 3321